Quantitative analysis for Gyre Therapeutics Inc. Common Stock (GYRE) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Sell (36.0) (grade D). 25 signals analyzed (20 differentiated alt-data).
GYRE stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $7.70 | $7.30 | $7.35 |
| 2026-05-11 | $7.45 | $7.20 | $7.26 |
| 2026-05-21 | $6.22 | $5.97 | $6.18 |
| 2026-06-03 | $5.73 | $5.50 | $5.69 |
| 2026-06-15 | $6.09 | $5.81 | $5.86 |
| 2026-06-26 | $6.49 | $6.23 | $6.29 |
| 2026-07-09 | $6.94 | $6.69 | $6.86 |
| 2026-07-21 | $6.14 | $5.87 | $6.06 |
| 2026-07-31 | $5.88 | $5.62 | $5.75 |
| 2026-08-12 | $6.98 | $6.62 | $6.66 |
| 2026-08-24 | $6.89 | $6.43 | $6.44 |
| 2026-09-03 | $6.54 | $6.36 | $6.44 |
How Gyre Therapeutics Inc. Common Stock stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| AZN | AstraZeneca PLC | $290.7B | — |
| NVS | Novartis AG | $287.1B | — |
| NVO | Novo Nordisk A/S | $200.3B | — |
| SNY | Sanofi | $107.6B | — |
View all Health Care stocks by valuation and signals →
Gyre Therapeutics Inc. Common Stock (GYRE) scores Sell (36.0), with every measured dimension at or below 51. The weakest are technicals at 25, competitive moat at 12, across 4 measured dimensions. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| earnings quality | 51 |
| valuation | 46 |
| technicals | 25 |
| competitive moat | 12 |
StoQuant analyzes 25 signals (20 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Gyre Therapeutics Inc. Common Stock (GYRE): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/GYRE"><img src="https://stoquant.com/badge/GYRE.svg" alt="Gyre Therapeutics Inc. Common Stock (GYRE) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.